Carregant...

Survival in melanoma brain metastases in the era of novel systemic therapies

BACKGROUND: Melanoma brain metastases (MBMs) have historically poor overall survival (OS). Recently introduced systemic anticancer therapies (SACTs), namely targeted therapies such as BRAF inhibitors and immunotherapy, to control advanced disease have shown improved survival. Today, increasingly agg...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neurooncol Adv
Autors principals: Merola, Joseph P, Ocen, Joanita, Kumar, Satish, Powell, James, Hayhurst, Caroline
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7764504/
https://ncbi.nlm.nih.gov/pubmed/33392503
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdaa144
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!